Bristol-Myers Squibb Company (0R1F.IL)
| Previous close | 45.45 |
| Open | 44.80 |
| Bid | 42.78 x N/A |
| Ask | 47.28 x N/A |
| Day's range | 44.35 - 45.34 |
| 52-week range | 44.35 - 69.08 |
| Volume | |
| Avg. volume | 179,713 |
| Market cap | 96.797B |
| Beta (5Y monthly) | 0.35 |
| PE ratio (TTM) | 12.14 |
| EPS (TTM) | 3.71 |
| Earnings date | 26 Jul 2024 |
| Forward dividend & yield | 2.28 (4.04%) |
| Ex-dividend date | 05 Oct 2023 |
| 1y target est | N/A |
- Yahoo Finance Video
Bristol Myers Squibb stock tumbles on cost-cutting initiative
Bristol Myers Squibb (BMY) shares are trading lower Thursday afternoon following the pharmaceutical company's announcement of several cost-cutting initiatives. Among the measures were workforce reductions and the termination of approximately 12 drug development programs. Yahoo Finance Health Reporter Anjalee Khemlani breaks down the details. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Angel Smith.
ZacksThe Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.
Business WireCHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
PRINCETON, N.J., April 26, 2024--CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine....
